Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation
Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients
Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment
Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows
New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study
REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infection
Liver cancer risk will remain elevated for people with cirrhosis cured of hepatitis C
Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3
